Is Neuren Pharmaceuticals Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Neuren Pharmaceuticals Ltd (NEU.AX) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Neuren Pharmaceuticals Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Neuren Pharmaceuticals Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Neuren Pharmaceuticals Ltd?

Muslim investors may consider investing in Neuren Pharmaceuticals Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Neuren Pharmaceuticals Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Neuren Pharmaceuticals Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Neuren Pharmaceuticals Ltd updated?

The Shariah compliance status of Neuren Pharmaceuticals Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Neuren Pharmaceuticals Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Neuren Pharmaceuticals Ltd?

You can check the latest Shariah compliance status of Neuren Pharmaceuticals Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

NEU.AX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 07, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for Neuren Pharmaceuticals Ltd (NEU.AX)

Based on 10 analysts giving stock ratings to Neuren Pharmaceuticals Ltd in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Neuren Pharmaceuticals Ltd. Stock Analysis NEU.AX

Australia Health Care Small Cap Report: 2025 Annual

Neuren Pharmaceuticals Ltd. engages in the development of new therapies for neurodevelopmental disorders that emerge in early childhood. The company is headquartered in Hawthorn, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product, NNZ-2591, is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.

Key Statistics of Neuren Pharmaceuticals Ltd (NEU.AX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

AUD12.75AUD13.12

Today's Open

AUD12.89

Volume

187.51K

P/E Ratio (TTM)

53.37

52 Week Range

AUD11.00AUD22.99

Market Cap

1.59B

Avg. Volume

94.53K

Dividend Yield

Financial Metrics & Statements of Neuren Pharmaceuticals Ltd (NEU.AX)

FAQ's for Neuren Pharmaceuticals Ltd (NEU.AX)

According to Musaffa’s Shariah screening methodology, Neuren Pharmaceuticals Ltd (NEU.AX) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.